ProfileGDS5678 / 1424008_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 40% 50% 52% 50% 47% 47% 58% 59% 50% 48% 50% 49% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1992549
GSM967853U87-EV human glioblastoma xenograft - Control 22.9241540
GSM967854U87-EV human glioblastoma xenograft - Control 33.1867150
GSM967855U87-EV human glioblastoma xenograft - Control 43.2000252
GSM967856U87-EV human glioblastoma xenograft - Control 53.1463850
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2088247
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1822547
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4903958
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5550259
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1834750
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1350348
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1678650
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1685849
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1739849